Welcome to this week's edition of The Targeted Pulse. This week in oncology, we saw a number of significant developments, ...

Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple ...

Berry and colleagues from the Institute for Healthcare Improvement and Henry Ford Health Detroit argue that deep, ...

In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, discusses his column from the September II 2025 issue.

During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.

FDA fast track is intended to expedite the development of therapies that fill serious unmet medical needs. With this ...

Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.

Following its Type A meeting with the FDA, Replimune reported that a forward pathway “has not been determined” to obtain ...

Carotuximab (ENV105) plus standard-of-care hormone therapy apalutamide (Erleada) demonstrated a progression-free survival ...

ADG126 is a novel anti–CTLA-4 agent incorporating protease-cleavable masking technology that enables tumor-specific ...